Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and teens. Between 10% to 20% of children with JIA have a rare and serious subtype called systemic juvenile idiopathic arthritis (SJIA). Symptoms of this rare disease can include overactivation of a type of immune cells called macrophages (MAS), unremitting fever, liver and spleen enlargement, abnormal bleeding, central nervous system dysfunction and other potential complications. Read about one family’s plight. Continue reading This SJIA Family Thrives in a New Setting
Hundreds of patients and their families, FDA staff, industry leaders, and researchers convened in Washington, D.C. to participate in the externally-led JIA Patient-Focused Drug Development (PFDD) meeting on August 2, 2018. The meeting served as a kickoff event to the 4-day Arthritis Foundation JA Conference East. Juvenile idiopathic arthritis (JIA) is the most common type of juvenile arthritis (JA). In many children, it’s a life-long illness with a high risk of disease and treatment-related morbidity. There is no cure, and treatments for children are limited.
This meeting, which is part of our strategy to help find a cure for this serious disease, provided an opportunity for patients, patient advocates, and caretakers to talk about the symptoms and issues that matter most to them. JIA parents and their families shared information about the impact of JIA on daily life, the symptoms that are most challenging, experiences with currently available treatments and the need for new and different treatments.
JIA patients and their families were invited to attend in-person and via a live webcast. They shared their experiences by responding to a live poll and discussion questions. Three patients and nine parent panelists told stories about how JIA impacts their daily lives and discussed the wide range of treatments they have tried.
Join us at the externally-led JIA Patient-Focused Drug Development meeting
We are hosting, along with our partner, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Juvenile Idiopathic Arthritis Patient-Focused Drug Development (PFDD) meeting. This meeting, driven by our patients and caregivers, will provide the U.S. Food and Drug Administration (FDA) and industry personnel with input directly from you on how this disease affects your life, your experiences with current treatments, and the need for newer and better treatments.
July may be best known for watching fireworks, eating ice cream and splashing in the pool. But it’s also the month when we recognize that one out of every 250 kids in the United States lives with some form of juvenile arthritis (JA).
Women who have juvenile idiopathic arthritis (JIA) – an umbrella term for several types of arthritis that develop in childhood appear to be at higher risk of developing heart disease than women who do not have inflammatory arthritis, according to a new study out of Canada. For years, researchers have examined the link between inflammatory forms of arthritis, such as rheumatoid arthritis (RA) or lupus, and an increased risk of heart disease. But no one had studied heart health in adults with JIA (another inflammatory form of arthritis), and little was known about the health effects of lifelong JIA during pregnancy.
Continue reading Women With Juvenile Arthritis May Be at Higher Risk of Heart Disease